![]() ![]() BESPC has conducted an investigation and believes that there is a valid basis to assert claims against the Company and its directors and/or officers for breach of fiduciary duties and other applicable laws. (“BESPC”) to represent you in connection with potential litigation against Checkmate Pharmaceuticals (the “Company”) and its directors and officers arising out of the. This will confirm that you have retained Bragar Eagel & Squire, P.C. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Checkmate’s stockholders. ![]() The deal is scheduled to close in mid-2022.īragar Eagel & Squire is concerned that Checkmate’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Pursuant to the merger agreement, Checkmate stockholders will receive $10.50 in cash for each share of Checkmate common stock owned. On April 19, 2022, Checkmate announced that it had entered into an agreement to be acquired by Regeneron in a deal valued at approximately $250 million. (NASDAQ: CMPI) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Regeneron Pharmaceuticals, Inc. NEW YORK, Ap– Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Checkmate Pharmaceuticals, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |